What is the most current recommendation for the treatment of latent tuberculosis?
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901257235464192 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Multiple regimens are recommended for LTBI treatment, including 3-month regimens of isoniazid and rifapentine or rifampicin, and 6 to 9 months of isoniazid, depending on patient risk and adherence considerations. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19254534 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | What is the most current recommendation for the treatment of latent tuberculosis? Tripdatabase latent tuberculosis treatment recommendation infectious diseases public health Multiple regimens are recommended for LTBI treatment, including 3-month regimens of isoniazid and rifapentine or rifampicin, and 6 to 9 months of isoniazid, depending on patient risk and adherence considerations. |
| title | What is the most current recommendation for the treatment of latent tuberculosis? |
| topic | latent tuberculosis treatment recommendation infectious diseases public health |
| url | https://doi.org/10.5281/zenodo.19254534 |